Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
…, V Ratziu, T Poynard, JM Castille… - Alimentary …, 2016 - Wiley Online Library
Background Blood tests of liver injury are less well validated in non‐alcoholic fatty liver disease
( NAFLD ) than in patients with chronic viral hepatitis. Aims To improve the validation of …
( NAFLD ) than in patients with chronic viral hepatitis. Aims To improve the validation of …
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population
…, O Deckmyn, Y Ngo, F Drane, JM Castille… - Journal of …, 2012 - Elsevier
BACKGROUND & AIMS: Time-dependent statistics have been used to assess liver fibrosis
progression (LFP) in liver diseases from birth to first biopsy, in a limited number of patients. …
progression (LFP) in liver diseases from birth to first biopsy, in a limited number of patients. …
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
…, MP Caulfield, JM Castille… - Journal of …, 2019 - journals.sagepub.com
Fibromax is a diagnostic tool composed of the combination of 4 non-invasive biomarker
panels for the diagnosis of steatosis (SteatoTest), necrosis and inflammation (ActiTest and …
panels for the diagnosis of steatosis (SteatoTest), necrosis and inflammation (ActiTest and …
[HTML][HTML] Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
…, Y Ngo, F Drane, D Messous, JM Castille… - BMC …, 2011 - Springer
Background FibroTest (FT) is a validated biomarker of fibrosis. To assess the applicability
rate and to reduce the risk of false positives/negatives (RFPN), security algorithms were …
rate and to reduce the risk of false positives/negatives (RFPN), security algorithms were …
Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes
…, E Larger, F Drane, JM Castille… - Alimentary …, 2021 - Wiley Online Library
Background One of the unmet needs in patients with type 2 diabetes mellitus (T2DM) is the
prediction of non‐alcoholic liver disease by non‐invasive blood tests, for each of the three …
prediction of non‐alcoholic liver disease by non‐invasive blood tests, for each of the three …
[HTML][HTML] Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
…, S Akhavan, V Calvez, C Franc, JM Castille… - PLoS …, 2020 - journals.plos.org
Background Since 1920, a decrease in serum cholesterol has been identified as a marker
of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the …
of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the …
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
…, M Munteanu, Y Ngo, F Drane, JM Castille… - BMJ open, 2015 - bmjopen.bmj.com
Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement
for a fibrosis score to support DDA reimbursement and a screening strategy, such as the …
for a fibrosis score to support DDA reimbursement and a screening strategy, such as the …
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes
…, R Liechti, O Martin, F Mehl, M Pruess, JM Castille… - Journal of …, 2024 - Elsevier
Background Non-invasive scores have been proposed to identify patients with fibrotic,
metabolic dysfunction associated steatohepatitis (MASH), who are at the highest risk of …
metabolic dysfunction associated steatohepatitis (MASH), who are at the highest risk of …
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19 (preprint)
…, M Vautier, S Akhavan, V Calvez, C Franc, JM Castille… - 2020 - pesquisa.bvsalud.org
Background Since 1920, a decrease in serum cholesterol has been identified as a marker
of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the …
of severe pneumonia. We have assessed the performance of serum apolipoprotein-A1, the …
APPLICABILITY AND RISK OF FALSE POSITIVE OR FALSE NEGATIVE RESULTS OF LIVER INJURY BIOMARKER FIBROTEST-FIBROSURE. A REAPPRAISAL AT 7 …
…, Y Ngo, F Drane, D Messous, JM Castille… - Hepatology, 2010 - journals.lww.com
Aim. FibroTest (FT) is a validated noninvasive biomarker of fibrosis. To reduce the risk of
false positives/negatives (RFPN), security algorithms were developed. The aims were to …
false positives/negatives (RFPN), security algorithms were developed. The aims were to …